Cellmid Limited (ASX: CDY) Spreads Its Wings Beyond Australian Shores

KEY TAKEAWAYS:

• Cellmid Ltd launched a new Advangen store in the prestigious Ginza shopping centre in Tokyo with the intention of encouraging people to discuss their hair loss issues and experiment with new products.
• In contrast to generalist retail, Cellmid and Advangen are striving to capitalize in specialist retail wherein customers will be provided with in-depth analysis of their hair related problem and recommended specific products to overcome it.
• After USA, Japan and Australia, Cellmid is now eyeing European and Asian markets to make its mark.

Cellmid Limited (ASX: CDY) inaugurated its first store in the Japanese Capital Tokyo. Located in the prestigious Ginza shopping centre, this outlet is based on the hair biology concept promulgated by health subsidiary Advangen and is meant to cater to middle-aged men and women who might be experiencing hair loss.

As opposed to generalist retail, specialist retail is a growing sector, particularly in the cosmetics segment and ample proof of this is evident from the rapid expansion of two prominent brands in the specialist cosmetics niche, namely ULTA and Sephora. By making a foray into this segment, Advangen hopes to cash in on the trend in consultative and experiential capacity. Its modus operandi entails inviting customers to the store to undergo hair assessment at the end of which they would be provided with the analysis.

Customers are also recommended specific products that they can use to overcome various hair related problems. Emphasis is laid on sale of FGF5 inhibitors and brands which Advangen has been selling since 2015 on QVC. It was in 2013 that Cellmid, an Australian company specializing in life sciences, took over the Japanese firm Advangen Inc. Subsequent to the acquisition, Cellmid has continued with Advangen’s research in the field of hair growth and has applied for patents for hair growth agents, FGF5 inhibitors being one of them.

Having acquired distribution rights in USA and Japan other than Australia, the company is now eyeing the shores of Europe and Asia to expand its frontiers and explore new horizons.

About Cellmid Ltd (ASX: CDY)

Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia.

Find Out More